New COVID-19 antibody enters first human safety trial
Disease control
Ongoing
This early-stage trial tests whether a new drug called PDI204, an antibody that targets the COVID-19 virus, is safe and tolerable in healthy adults. 32 participants will receive a single dose of PDI204 or a placebo and be monitored for side effects and how the drug behaves in the…
Phase: PHASE1 • Sponsor: University of Melbourne • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC